ENZYME2 Pharmaceuticals

Fighting Covid19 by using 3 ways for drug small molecules

Bulgaria
Market: Medicine
Stage of the project: Prototype or product is ready

Date of last change: 29.04.2020

Go to the owner's profile

from 2000

Calculated and estimated occupancy of the project (more about ratings)

My rating

Average rating:

Idea

Enzyme2 fighting Coronaviruses (Covid-19) by using 3 approaches for novel drug small molecules. Repurpose our first in class molecules in CCR5/CCR7 antagonists and SLC6A5 proprietary inhibitors and optimize our new ACE2 allosteric binders for the treatment of all patients affected by COVID-19 and other related coronaviruses.

Current Status

We built unique drug candidates for treatment of pandemic COVID-19 & Coronaviruses by using 3 approaches with novel first in class drug molecules.

Market

Current Market Potential Validation: https://coronavirus.jhu.edu/map.html

Apart from the tragic human consequences of the COVID-19 coronavirus epidemic, the economic uncertainty it has sparked will likely cost the global economy $ 1-2 Trillion in 2020
Source: according to the UN’s trade and development agency, UNCTAD

Problem or Opportunity

We built unique drug candidates for treatment of pandemic COVID-19 & Coronaviruses

Solution (product or service)

We built unique drug candidates for treatment of pandemic COVID-19 & Coronaviruses
Our novel small molecules contributes to: • Treatment of pandemic COVID-19 & Coronaviruses
• Reduces direct economic healthcare costs • Positive social and economic impact globally
By using:
- Micar21 new classes of Glycine transporter 2 (GlyT2) Inhibitors
- Micar21 the first class of “Ortho” CCR7 antagonists

Competitors

Micar21 in World analytic reports / COMPETITORS

Micar21, is one of the world’s 198 companies in Roots Analysis Study report: “In Silico/Computer-Aided Drug Discovery Services Market 2020-2030” Source: https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

Micar21, is one of the world’s 130 companies in Deep Knowledge Analytics report: AI for Drug Discovery Landscape 2018, 2019, 2020
Source: https://www.dka.global/

Micar21, is one of the world’s 250 companies in Roots Analysis Study report: “Computer-Aided Drug Discovery Services Market 2018-2030”
Source: https://www.rootsanalysis.com/reports/view_document/computer-aided-drug-discovery-services-market-2018-2030/207.html

16 Deep Tech Startups From The Balkans To Watch In 2020
TrendingTopics
Source: https://www.trendingtopics.at/bulgaria/16-deep-tech-startups-from-the-balkans-to-watch-in-2020/

LANDSCAPE SOFIA 2020
TNW X
Source: http://tiny.cc/tt5nmz

Advantages or differentiators

The three ways approach of curing COVID-19 offers a very elegant and cost effective way and garantes success, while minimizing risks.

Finance

We can share business plan for next 20 years.

Business model

ENZYME2 business model is based on discovering and developing COVID-19 first in class candidates until Phase 2a “Proof of concept" (PoC) and licensing them to youour commercial partner.